PFE · Pfizer Inc.
$24.292026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$105
+332.7% vs market
Base · active
$30
+21.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($30 · $105) Analysts Range ($25 · $30) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $59.6B | — | 11.0% | 45.0% | $3.6B | −$39.9B | −$36.3B | 6.9% | — | 2.0% | $178.5B | $0.37 | — |
| 2024.Q4 | $59.6B | 0.0% | 11.0% | 0.0% | $6.5B | $5.0B | $11.6B | 6.6% | — | 3.9% | $160.8B | $0.37 | — |
| 2025.Q1 | $63.6B | 6.8% | 31.9% | 0.0% | $21.7B | $9.2B | $31.0B | 6.2% | — | 13.4% | $164.2B | $1.40 | — |
| 2025.Q4 | $63.6B | 0.0% | 31.9% | 0.0% | $21.0B | −$4.5B | $16.5B | 6.4% | — | 12.7% | $167.9B | $1.40 | — |
| 2026.Q1 | $63.3B | -0.5% | 28.9% | 4.9% | $17.4B | −$11.0B | $6.4B | 5.7% | — | 10.2% | $174.8B | $1.31 | 7.6 |
| italics below = DCF projection · 10yr Rev CAGR: 0.4% |
| 2027.Q1 | $61.1B | +-3.5% | 30.7% | 6.4% | $17.6B | $0MM | $17.6B | 6.0% | $16.6B | 10.1% | $174.8B | $2.49 | 9.8 |
| 2028.Q1 | $59.5B | +-2.6% | 28.0% | 7.9% | $15.4B | $0MM | $15.4B | 6.2% | $13.6B | 8.8% | $174.8B | $2.17 | 11.2 |
| 2029.Q1 | $58.4B | +-1.8% | 21.8% | 9.4% | $11.6B | $0MM | $11.6B | 6.5% | $9.6B | 6.6% | $174.8B | $1.64 | 14.8 |
| 2030.Q1 | $57.9B | +-0.9% | 27.8% | 10.9% | $14.3B | $0MM | $14.3B | 6.8% | $11.2B | 8.2% | $174.8B | $2.03 | 12.0 |
| 2031.Q1 | $58.4B | +0.8% | 27.8% | 12.4% | $14.2B | $0MM | $14.2B | 7.0% | $10.4B | 8.1% | $174.8B | $2.01 | 12.1 |
|
| Term. Yr+ | $68.4B | 4.1% | 33.0% | 20.0% | $18.1B | −$8.6B | $9.5B | 8.6% | $105.3B | 8.6% | — | — | — |
Active scenario IV: $30 (+21.6% vs market)